Drug Trial Radar · NCT05641272
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 1, 2023
Primary completion
Jun 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Inmunotek S.L.Industry
- Sponsor type
- Industry
- Collaborators
- LAT Research; Xolomon Tree S.L.
- First posted
- Dec 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic rhinitis/rhinoconjunctivitis with or without asthma. The main objective of the clinical trial is to evaluate the clinical efficacy of the investigational medicinal product, administered sublingually, compared to placebo for the treatment of moderate-severe rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and controlled using the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (R-CSMS).
Conditions
- Allergic Rhinitis
- Allergic Asthma
- Allergic Rhinoconjunctivitis
- Allergy to House Dust Mite
Interventions
3,000 MM09Biological
Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
9,000 MM09Biological
Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
Placebo sublingualOther
The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rhinitis/rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS)Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fundación CIDEA
Buenos Aires, Paraguay, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.